Psyched Wellness (CSE:PSYC, FRA:5U9, OTCQB:PSYCF) Ltd. has announced that, in collaboration with KGK, a licensed CRO in Canada, it is commencing the next preclinical trial study on Amanita Muscaria Extract (AME-1).
The trial will comprise a neurobehavioral study focusing on determining the neurotoxicity effects of AME-1 on functional and motor activity, and in conjunction with the other toxicity studies, will provide scientific evidence for the efficacy and safety of AME-1.
In a statement, Brian Tancowny, scientific advisor to Psyched Wellness (CSE:PSYC, FRA:5U9, OTCQB:PSYCF), commented: "This study is another key step in understanding the effects of (AME-1), in pursuit of a safe dosing regimen for human consumption. The results of this study will further enhance the Company's knowledge of AME-1 and further identify in a scientific setting any behavioral and neurological functional changes with the use of AME-1."
READ: Psyched Wellness submits applications to US Patent and Trademark office for four further provisional patents surrounding its flagship AME-1 product
The study will involve non-invasive observational measures assessing neurological, motor and functional integrity, which are critical indicators to measuring neural function.
Jeff Stevens, CEO of Psyched, commented: "This preclinical trial study moves the Company closer to being able to market our products in 2022 which are aimed at helping relaxation, stress relief, and better sleep. Psyched will be the first company to complete the extensive scientific trials on Amanita Muscaria in order to position AME-1 as the first extract of the fungi that is legal for human consumption in the health and wellness markets."
Psyched Wellness is a Canadian-based health supplements company dedicated to the distribution of mushroom-derived products and associated consumer packaged goods. The company's objective is to create premium mushroom-derived products that have the potential to become a leading North American brand in the emerging functional food category.
It is in the process of developing a line of Amanita muscaria-derived water-based extracts, teas and capsules designed to help with three health objectives: promote stress relief, relaxation and assist with restful sleeping.
Contact the author at jon.hopkins@proactiveinvestors.com